Anker SD; for the FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF studyChronic heart failureIron deficiencyRenal functionFerric carboxymaltoseAimsAnaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic...
Red cell distribution width (RDW), a measure of variability in red blood cell size, is a novel prognostic marker in chronic heart failure (CHF). Iron deficiency contributes to elevated RDW. In the FAIR-HF trial, i.v. ferric carboxymaltose (FCM) improved the 6 min walk test (6MWT) dista...
摘要: Publication » PCV65 HEALTH ECONOMIC ASSESSMENT OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY AND CHRONIC HEART FAILURE IN THE FAIR-HF TRIAL.DOI: 10.1016/S1098-3015(11)72408-1 被引量: 41 年份: 2010 收藏 引用 批量引用 报错 分享 全部来源 免费下载 求助全文 Elsevier (...
Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail 2010;12:1159 -1162.Gonzalez-Castello J, Comin-Colet J. Iron deficiency and anae- mia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail 2010;12:1159-1162....
Cost-effectiveness of ferric carboxymaltose in patients with chronic heart failure: an analysis from the FAIR-HF trial (abstract no. P1437). Eur Heart J. 2010;31(Suppl 1):225.Blank, PR, Schwenkglenks, M, Szucs, TD (2010) Cost-effectiveness of ferric carboxymaltose in p...
Eur J Heart Fail 2015; 17: 329-339.Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD; FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose ...
Chicago, Illinois, USA: Amercan Heart Association; 2010.Ponikowski P, et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Abstract presented at Late Breaking Trial Session, HFA 2010